Cargando…

Long‐term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus

AIM: The aim of this study was to assess the long‐term efficacy and safety of canagliflozin as add‐on therapy in Japanese patients with type 2 diabetes mellitus who had inadequate glycaemic control with insulin. MATERIALS AND METHODS: The study comprised a 16‐week, double‐blind period in which patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inagaki, Nobuya, Harashima, Shin‐ichi, Kaku, Kohei, Kondo, Kazuoki, Maruyama, Nobuko, Otsuka, Makiko, Kawaguchi, Yutaka, Iijima, Hiroaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873413/ https://www.ncbi.nlm.nih.gov/pubmed/29110384 http://dx.doi.org/10.1111/dom.13152

Ejemplares similares

Efficacy and safety of canagliflozin as add‐on therapy to a glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week, open‐label, phase IV study
por: Harashima, Shin‐ichi, et al.
Publicado: (2018)

Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus
por: Inagaki, Nobuya, et al.
Publicado: (2016)

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
por: Iijima, Hiroaki, et al.
Publicado: (2015)

Long‐term safety and efficacy of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes
por: Kadowaki, Takashi, et al.
Publicado: (2017)

Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24‐week, randomized, double‐blind, placebo‐controlled trial
por: Kadowaki, Takashi, et al.
Publicado: (2017)

Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, placebo‐controlled, parallel‐group comparative study
por: Kadowaki, Takashi, et al.
Publicado: (2017)

Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
por: Inagaki, Nobuya, et al.
Publicado: (2015)

Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus
por: Tanaka, Hiroyuki, et al.
Publicado: (2016)

Pharmacokinetic and Pharmacodynamic Profiles of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment
por: Inagaki, Nobuya, et al.
Publicado: (2014)

Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study
por: Inagaki, Nobuya, et al.
Publicado: (2015)

Intra‐ and inter‐subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co‐transporter 2 inhibitor canagliflozin
por: Polidori, David, et al.
Publicado: (2018)

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus
por: Seino, Yutaka, et al.
Publicado: (2015)

Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy
por: Kaku, Kohei, et al.
Publicado: (2014)

Sphingosine kinase 1-interacting protein is a novel regulator of glucose-stimulated insulin secretion
por: Wang, Yu, et al.
Publicado: (2017)

Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study†
por: Inagaki, N, et al.
Publicado: (2013)

Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial
por: Kaku, Kohei, et al.
Publicado: (2019)

Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus
por: Kadowaki, Takashi, et al.
Publicado: (2013)

Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open‐label study in Japan
por: Nangaku, Masaomi, et al.
Publicado: (2020)

A Large Difference in Dose Timing of Basal Insulin Introduces Risk of Hypoglycemia and Overweight: A Cross-Sectional Study
por: Nishimura, Akiko, et al.
Publicado: (2017)

Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study
por: Fushimi, Yoshiro, et al.
Publicado: (2020)

Long-Term Effect of the Color Record Method in Self-Monitoring of Blood Glucose on Metabolic Parameters in Type 2 Diabetes: A 2-Year Follow-up of the Color IMPACT Study
por: Nishimura, Akiko, et al.
Publicado: (2018)

Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan
por: Kadowaki, Takashi, et al.
Publicado: (2022)

Social Orientation and Diabetes-Related Distress in Japanese and American Patients with Type 2 Diabetes
por: Ikeda, Kaori, et al.
Publicado: (2014)

Sorting nexin 19 regulates the number of dense core vesicles in pancreatic β‐cells
por: Harashima, Shin‐ichi, et al.
Publicado: (2011)

Insulin degludec in Japanese patients with type 1 diabetes mellitus: A randomized controlled trial
por: Iwamoto, Yasuhiko, et al.
Publicado: (2013)

Efficacy and safety of once‐weekly oral trelagliptin switched from once‐daily dipeptidyl peptidase‐4 inhibitor in patients with type 2 diabetes mellitus: An open‐label, phase 3 exploratory study
por: Inagaki, Nobuya, et al.
Publicado: (2017)

Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance
por: Inagaki, Nobuya, et al.
Publicado: (2021)

Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial
por: Kondo, Yaeko, et al.
Publicado: (2016)

Sex-related differences in frailty factors in older persons with type 2 diabetes: a cross-sectional study
por: Nishimura, Akiko, et al.
Publicado: (2019)

Long‐term safety and efficacy of a novel once‐weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52‐week open‐label, phase 3 study
por: Inagaki, Nobuya, et al.
Publicado: (2016)

Association between glycemic control and cardiovascular events in older Japanese adults with diabetes mellitus: An analysis of the Japanese medical administrative database
por: Yokote, Koutaro, et al.
Publicado: (2021)

Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from Japan
por: Kaku, Kohei, et al.
Publicado: (2015)

Effects of glucose and meal ingestion on incretin secretion in Japanese subjects with normal glucose tolerance
por: Yamane, Shunsuke, et al.
Publicado: (2011)

Insulin secretory capacity and insulin sensitivity in impaired fasting glucose in Japanese
por: Mitsui, Rie, et al.
Publicado: (2012)

Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post‐hoc analysis of a phase 3 randomized clinical trial
por: Kaneko, Shizuka, et al.
Publicado: (2018)

A phase 3, open‐label, single‐arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis‐stimulating agents
por: Nangaku, Masaomi, et al.
Publicado: (2021)

Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients
por: Ikushima, Ippei, et al.
Publicado: (2015)

Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study
por: Nangaku, Masaomi, et al.
Publicado: (2021)

Efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double‐blind, phase 3 trial
por: Kaku, Kohei, et al.
Publicado: (2019)

CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice
por: Woo, Vincent, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rfdvi2j0oukmodfg03vc0lm6c5